Thrombotic microangiopathies as a prime example for translational medicine

Peter F. Zipfel

doi:10.1160/TH08-12-0819

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2009; 101(02): 225-226
DOI: 10.1160/TH08-12-0819

Theme Issue Editorial

Schattauer GmbH

Thrombotic microangiopathies as a prime example for translational medicine

Peter F. Zipfel

¹Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology and Friedrich-Schiller-University, Jena, Germany

References
1 Skerka C, Jozsi M, Zipfel P. et al. Autoantibodies in hemolytic uremic syndrome (HUS). Thromb Haemost 2009; 101: 227-232.
2 Bresin E, Gastoldi S, Diana E. et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenia purpura and evidence of anti-adamts13 autoantibodies. Thromb Haemost 2009; 101: 233-238.
3 Claus R, Bockmeyer C, Budde U. et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-247.
4 Gerth J, Schleussner E, Kentouche K. et al. Pregnancy- associated thrombotic thrombocytopenic purpura. Thromb Haemost 2009; 101: 248-251.
5 Müthing J, Schweppe C, Karch H. et al. Shiga toxins, glycosphingolipid diversity and endothelial cell injury. Thromb Haemost 2009; 101: 252-264.
6 Amann K, Benz K. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uremic syndrome (HUS) / thrombocytic thrombopenic purpura (TTP). Thromb Haemost 2009; 101: 265-270.
7 Licht C, Fremeaux-Bacchi V. Hereditary and Acquired Complement Dysregulation in Membranoproliferative Glomerulonephritis. Thromb Haemost 2009; 101: 271-278.